Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication
- PMID: 10983634
- DOI: 10.1097/00002030-200007280-00003
Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication
Abstract
Objective: To model the dynamics of HIV-1 rebound in patients receiving suboptimal therapy after suppression of plasma viremia to < 200 copies/ml by triple combination therapy.
Design: Mathematical modeling of data from 23 patients switched to indinavir maintenance therapy after viral replication was suppressed with a combination of indinavir, zidovudine and lamivudine. Modeling of HIV-1 rebound among 24 patients on zidovudine/lamivudine maintenance was also performed for comparison.
Methods: Evaluation of slopes of rebound and of their heterogeneity; calculation of the basic reproductive number (Ro, the number of newly infected cells arising from each productively infected cell); regression analyses for predictors of the slope of rebound.
Results: Rebound of plasma HIV RNA followed a sigmoid curve with an initial exponential phase. There was significant heterogeneity in the slopes of rebound for individual patients (P < 0.001). In the indinavir maintenance rebounds, the average initial slope was estimated to be 0.587/day (doubling time 1.2 days). The slopes of rebound in patients on zidovudine/lamivudine maintenance tended to be less steep on average (P = 0.025). Among patients taking indinavir maintenance, the average Ro for the initial rebound of viremia was 4.3; in multivariate regressions, the slope of rebound was steeper during early rebound and in patients with higher viral load at the start of triple therapy or a higher CD4 cell count when indinavir monotherapy was initiated. The slope was less steep in patients with a greater increase in the number of CD4 cells during triple therapy.
Conclusions: The rates of viral load increase among patients with viral rebound while receiving less than triple therapy are similar to those reported in patients interrupting therapy. Variability among patients may depend on viral fitness, target cell availability and extent of immune reconstitution.
Similar articles
-
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.JAMA. 2001 Mar 7;285(9):1155-63. doi: 10.1001/jama.285.9.1155. JAMA. 2001. PMID: 11231744 Clinical Trial.
-
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.N Engl J Med. 1998 Oct 29;339(18):1261-8. doi: 10.1056/NEJM199810293391801. N Engl J Med. 1998. PMID: 9791141 Clinical Trial.
-
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.AIDS. 2000 Mar 10;14(4):367-74. AIDS. 2000. PMID: 10770538 Clinical Trial.
-
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.Ann Intern Med. 2000 Sep 19;133(6):435-8. doi: 10.7326/0003-4819-133-6-200009190-00011. Ann Intern Med. 2000. PMID: 10975961 Review.
-
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.Antivir Ther. 2011;16(8):1149-67. doi: 10.3851/IMP1919. Antivir Ther. 2011. PMID: 22155899 Review.
Cited by
-
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.PLoS One. 2012;7(3):e34134. doi: 10.1371/journal.pone.0034134. Epub 2012 Mar 30. PLoS One. 2012. PMID: 22479542 Free PMC article. Clinical Trial.
-
Cocaine promotes both initiation and elongation phase of HIV-1 transcription by activating NF-κB and MSK1 and inducing selective epigenetic modifications at HIV-1 LTR.Virology. 2015 Sep;483:185-202. doi: 10.1016/j.virol.2015.03.036. Epub 2015 May 15. Virology. 2015. PMID: 25980739 Free PMC article.
-
The effects of cocaine on HIV transcription.J Neurovirol. 2016 Jun;22(3):261-74. doi: 10.1007/s13365-015-0398-z. Epub 2015 Nov 16. J Neurovirol. 2016. PMID: 26572787 Free PMC article. Review.
-
Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.PLoS One. 2016 May 18;11(5):e0154842. doi: 10.1371/journal.pone.0154842. eCollection 2016. PLoS One. 2016. PMID: 27191165 Free PMC article. Clinical Trial.
-
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.J Infect Dis. 2011 Apr 1;203(7):976-83. doi: 10.1093/infdis/jiq143. J Infect Dis. 2011. PMID: 21402549 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials